Rigel Pharmaceuticals Inc Financials

RIGL

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Rigel Pharmaceuticals Inc (RIGL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 67/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Rigel Pharmaceuticals Inc has an operating margin of 13.5%, meaning the company retains $13 of operating profit per $100 of revenue. This strong profitability earns a score of 67/100, reflecting efficient cost management and pricing power. This is up from -17.5% the prior year.

Growth

100

Rigel Pharmaceuticals Inc's revenue surged 53.4% year-over-year to $179.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Rigel Pharmaceuticals Inc has elevated debt relative to equity (D/E of 18.25), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

With a current ratio of 2.13, Rigel Pharmaceuticals Inc holds $2.13 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 65/100.

Returns

100

Rigel Pharmaceuticals Inc earns a strong 531.8% return on equity (ROE), meaning it generates $532 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.

Altman Z-Score Distress

-7.44

Rigel Pharmaceuticals Inc scores -7.44, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($623.0M) relative to total liabilities ($160.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Strong

7/9

Rigel Pharmaceuticals Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.80x

For every $1 of reported earnings, Rigel Pharmaceuticals Inc generates $1.80 in operating cash flow ($31.5M OCF vs $17.5M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

3.1x

Rigel Pharmaceuticals Inc earns $3.1 in operating income for every $1 of interest expense ($24.2M vs $7.9M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Revenue

$179.3M

YoY+53.4%

5Y CAGR+24.8%

Rigel Pharmaceuticals Inc generated $179.3M in revenue in fiscal year 2024. This represents an increase of 53.4% from the prior year.

EBITDA

$26.4M

YoY+237.2%

Rigel Pharmaceuticals Inc's EBITDA was $26.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 237.2% from the prior year.

Free Cash Flow

N/A

Net Income

$17.5M

YoY+169.7%

Rigel Pharmaceuticals Inc reported $17.5M in net income in fiscal year 2024. This represents an increase of 169.7% from the prior year.

EPS (Diluted)

$0.99

YoY+168.7%

Rigel Pharmaceuticals Inc earned $0.99 per diluted share (EPS) in fiscal year 2024. This represents an increase of 168.7% from the prior year.

Cash & Debt

$56.7M

YoY+73.1%

5Y CAGR+20.3%

10Y CAGR+14.1%

Rigel Pharmaceuticals Inc held $56.7M in cash against $60.0M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY+1.3%

Rigel Pharmaceuticals Inc had 18M shares outstanding in fiscal year 2024. This represents an increase of 1.3% from the prior year.

Gross Margin

89.6%

YoY-4.3pp

5Y CAGR-8.9pp

Rigel Pharmaceuticals Inc's gross margin was 89.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 4.3 percentage points from the prior year.

Operating Margin

13.5%

YoY+31.0pp

5Y CAGR+130.0pp

Rigel Pharmaceuticals Inc's operating margin was 13.5% in fiscal year 2024, reflecting core business profitability. This is up 31.0 percentage points from the prior year.

Net Margin

9.8%

YoY+31.2pp

5Y CAGR+122.6pp

Rigel Pharmaceuticals Inc's net profit margin was 9.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 31.2 percentage points from the prior year.

Return on Equity

531.8%

Rigel Pharmaceuticals Inc's ROE was 531.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.

R&D Spending

$23.4M

YoY-4.7%

5Y CAGR-15.1%

10Y CAGR-10.1%

Rigel Pharmaceuticals Inc invested $23.4M in research and development in fiscal year 2024. This represents a decrease of 4.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RIGL Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$179.3M+53.4%	$116.9M-2.8%	$120.2M-19.4%	$149.2M+37.4%	$108.6M+83.2%	$59.3M
Cost of Revenue	$18.6M+162.3%	$7.1M+306.5%	$1.7M+61.5%	$1.1M+21.0%	$895K-1.2%	$906K
Gross Profit	$160.6M+46.3%	$109.8M-7.4%	$118.5M-20.0%	$148.2M+37.5%	$107.7M+84.5%	$58.4M
R&D Expenses	$23.4M-4.7%	$24.5M-59.3%	$60.3M-7.6%	$65.2M+8.5%	$60.1M+13.6%	$52.9M
SG&A Expenses	$113.1M+6.9%	$105.7M-6.0%	$112.5M+22.4%	$91.9M+20.0%	$76.6M+2.7%	$74.6M
Operating Income	$24.2M+218.1%	-$20.5M+63.1%	-$55.5M-344.5%	-$12.5M+56.9%	-$29.0M+58.1%	-$69.1M
Interest Expense	$7.9M+15.2%	$6.9M+85.4%	$3.7M-23.7%	$4.9M+259.2%	$1.4M+303.9%	$335K
Income Tax	$881K	N/A	N/A	$605K	N/A	N/A
Net Income	$17.5M+169.7%	-$25.1M+57.2%	-$58.6M-227.0%	-$17.9M+39.8%	-$29.7M+55.5%	-$66.9M
EPS (Diluted)	$0.99+168.7%	$-1.44	$-3.44-3027.3%	$-0.11+38.9%	$-0.18+55.0%	$-0.40

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$69.5M-31.7%	$101.7M+90.7%	$53.3M-7.4%	$57.6M+56.3%	$36.8M+24.7%	$29.5M-17.5%	$35.8M+27.2%	$28.1M
Cost of Revenue	$4.8M+5.5%	$4.5M+2.2%	$4.4M-23.8%	$5.8M+106.2%	$2.8M+38.6%	$2.0M-46.6%	$3.8M+198.9%	$1.3M
Gross Profit	$64.7M-33.4%	$97.2M+98.6%	$48.9M-5.6%	$51.8M+52.2%	$34.0M+23.7%	$27.5M-14.0%	$32.0M+19.1%	$26.9M
R&D Expenses	$7.4M+7.8%	$6.8M-19.1%	$8.4M+49.8%	$5.6M+1.7%	$5.5M-8.1%	$6.0M+89.1%	$3.2M-50.8%	$6.5M
SG&A Expenses	$28.9M-1.1%	$29.3M+5.6%	$27.7M-6.1%	$29.5M+5.3%	$28.0M-1.4%	$28.4M+6.0%	$26.9M+8.0%	$24.9M
Operating Income	$28.4M-53.5%	$61.1M+378.4%	$12.8M-23.3%	$16.7M+3626.0%	$447K+106.4%	-$7.0M-454.3%	$2.0M+144.0%	-$4.5M
Interest Expense	$1.9M+1.1%	$1.9M+1.1%	$1.9M-5.2%	$2.0M-3.6%	$2.0M+8.3%	$1.9M-1.7%	$1.9M+0.4%	$1.9M
Income Tax	-$280K-175.9%	$369K+467.7%	$65K-92.6%	$881K	$0	$0	N/A	N/A
Net Income	$27.9M-53.2%	$59.6M+420.8%	$11.4M-20.2%	$14.3M+1492.3%	-$1.0M+87.5%	-$8.2M-1219.0%	$737K+112.9%	-$5.7M
EPS (Diluted)	$1.46-55.5%	$3.28+420.6%	$0.63-23.2%	$0.82+1466.7%	$-0.06	$-0.47	$-0.65	$-0.33

RIGL Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$164.0M+39.9%	$117.2M-12.7%	$134.3M-19.8%	$167.3M+51.6%	$110.4M-25.2%	$147.6M
Current Assets	$135.1M+36.1%	$99.3M-14.4%	$115.9M-25.0%	$154.5M+73.6%	$89.0M-25.2%	$119.0M
Cash & Equivalents	$56.7M+73.1%	$32.8M+34.0%	$24.5M+29.5%	$18.9M-37.8%	$30.4M+34.9%	$22.5M
Inventory	$6.0M+8.7%	$5.5M-39.4%	$9.1M+37.8%	$6.6M+303.9%	$1.6M+21.0%	$1.4M
Accounts Receivable	$41.6M+36.2%	$30.6M-24.2%	$40.3M+160.6%	$15.5M-3.1%	$16.0M+58.0%	$10.1M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$160.7M+10.2%	$145.9M-1.4%	$147.9M+8.0%	$137.0M+79.4%	$76.4M-18.6%	$93.8M
Current Liabilities	$63.3M+18.8%	$53.3M-18.3%	$65.2M+2.6%	$63.6M+55.6%	$40.8M-29.8%	$58.2M
Long-Term Debt	$60.0M0.0%	$60.0M+50.0%	$40.0M+100.0%	$20.0M0.0%	$20.0M+100.0%	$10.0M
Total Equity	$3.3M+111.5%	-$28.6M-110.4%	-$13.6M-144.8%	$30.4M-10.7%	$34.0M-36.8%	$53.8M
Retained Earnings	-$1.4B+1.2%	-$1.4B-1.8%	-$1.4B-4.4%	-$1.3B-1.4%	-$1.3B-2.3%	-$1.3B

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$242.5M+17.3%	$206.7M+17.5%	$176.0M+7.3%	$164.0M+27.7%	$128.4M+1.5%	$126.5M+7.9%	$117.2M+1.6%	$115.3M
Current Assets	$214.9M+22.5%	$175.4M+19.7%	$146.6M+8.5%	$135.1M+42.6%	$94.7M+2.4%	$92.5M-6.8%	$99.3M+4.5%	$95.0M
Cash & Equivalents	$48.5M-9.1%	$53.4M+16.8%	$45.7M-19.4%	$56.7M+57.4%	$36.1M+41.0%	$25.6M-22.0%	$32.8M-27.8%	$45.4M
Inventory	$13.3M+27.6%	$10.4M+123.7%	$4.7M-22.4%	$6.0M-25.5%	$8.1M+22.5%	$6.6M+19.1%	$5.5M-9.7%	$6.1M
Accounts Receivable	$45.9M+15.1%	$39.9M-3.9%	$41.5M-0.2%	$41.6M+44.0%	$28.9M+5.1%	$27.5M-9.9%	$30.6M+29.7%	$23.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$124.9M+0.1%	$124.8M-20.7%	$157.4M-2.0%	$160.7M+1.5%	$158.3M+0.1%	$158.2M+8.4%	$145.9M-0.9%	$147.2M
Current Liabilities	$94.4M+9.0%	$86.6M+30.0%	$66.6M+5.3%	$63.3M+7.9%	$58.6M-19.9%	$73.2M+37.4%	$53.3M+10.3%	$48.3M
Long-Term Debt	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M
Total Equity	$117.6M+43.5%	$81.9M+341.3%	$18.6M+464.7%	$3.3M+111.0%	-$29.9M+5.5%	-$31.7M-10.6%	-$28.6M+10.0%	-$31.8M
Retained Earnings	-$1.3B+2.1%	-$1.3B+4.3%	-$1.4B+0.8%	-$1.4B+1.9%	-$1.4B-0.1%	-$1.4B-0.6%	-$1.4B+0.1%	-$1.4B

RIGL Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$31.5M+648.0%	-$5.7M+92.2%	-$73.8M-1354.8%	$5.9M+111.3%	-$52.2M-25.7%	-$41.5M
Capital Expenditures	N/A	N/A	$450K-28.2%	$627K-50.3%	$1.3M-13.3%	$1.5M
Free Cash Flow	N/A	N/A	-$74.2M-1513.2%	$5.3M+109.8%	-$53.4M-24.4%	-$43.0M
Investing Cash Flow	$4.1M+196.1%	-$4.3M-105.9%	$72.8M+190.9%	-$80.0M-268.6%	$47.5M+300.7%	-$23.7M
Financing Cash Flow	-$11.6M-163.4%	$18.4M+180.4%	$6.5M-89.5%	$62.7M+398.6%	$12.6M+10.6%	$11.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	$24.0M-21.3%	$30.5M+3519.6%	-$893K-106.2%	$14.5M+4702.3%	$302K+106.0%	-$5.0M+19.7%	-$6.2M-359.2%	-$1.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$33.2M-42.5%	-$23.3M-120.6%	-$10.6M+3.3%	-$10.9M-199.9%	$10.9M+3391.7%	$313K+104.6%	-$6.9M-487.5%	-$1.2M
Financing Cash Flow	$4.3M+921.8%	$418K-13.6%	$484K-67.0%	$1.5M+294.8%	-$752K+70.1%	-$2.5M-616.9%	$486K+155.9%	-$869K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RIGL Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	89.6%-4.3pp	93.9%-4.6pp	98.6%-0.7pp	99.3%+0.1pp	99.2%+0.7pp	98.5%
Operating Margin	13.5%+31.0pp	-17.5%+28.7pp	-46.2%-37.8pp	-8.4%+18.3pp	-26.7%+89.9pp	-116.5%
Net Margin	9.8%+31.2pp	-21.5%+27.2pp	-48.7%-36.7pp	-12.0%+15.4pp	-27.4%+85.5pp	-112.8%
Return on Equity	531.8%	N/A	N/A	N/A	N/A	N/A
Return on Assets	10.7%+32.1pp	-21.4%+22.2pp	-43.6%-32.9pp	-10.7%+16.2pp	-27.0%+18.4pp	-45.3%
Current Ratio	2.13+0.3	1.86+0.1	1.78-0.7	2.43+0.3	2.18+0.1	2.04
Debt-to-Equity	18.25+20.3	-2.09+0.8	-2.94-3.6	0.66+0.1	0.59+0.4	0.19
FCF Margin	N/A	N/A	-61.7%-65.2pp	3.5%+52.7pp	-49.2%+23.3pp	-72.5%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	93.2%-2.4pp	95.6%+3.8pp	91.7%+1.8pp	90.0%-2.4pp	92.4%-0.8pp	93.1%+3.7pp	89.4%-6.1pp	95.5%
Operating Margin	40.9%-19.2pp	60.1%+36.1pp	23.9%-5.0pp	28.9%+27.7pp	1.2%+24.8pp	-23.6%-29.1pp	5.5%+21.4pp	-15.9%
Net Margin	40.2%-18.5pp	58.6%+37.2pp	21.5%-3.4pp	24.9%+27.7pp	-2.8%+25.1pp	-27.9%-30.0pp	2.1%+22.3pp	-20.2%
Return on Equity	23.7%-49.0pp	72.8%+11.1pp	61.7%-374.5pp	436.2%	N/A	N/A	N/A	N/A
Return on Assets	11.5%-17.3pp	28.8%+22.3pp	6.5%-2.2pp	8.8%+9.6pp	-0.8%+5.7pp	-6.5%-7.1pp	0.6%+5.6pp	-4.9%
Current Ratio	2.28+0.3	2.02-0.2	2.20+0.1	2.13+0.5	1.62+0.4	1.26-0.6	1.86-0.1	1.97
Debt-to-Equity	0.51-0.2	0.73-2.5	3.23-15.0	18.25+20.3	-2.01-0.1	-1.89+0.2	-2.09-0.2	-1.88
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Palvella Therapeutics Inc PVLA

$965.1M

Nurix Therapeutics, Inc. NRIX

$1.6B

Rezolute Inc RZLT

$356.1M

Terns Pharmaceuticals, Inc. TERN

$4.1B

Anaptysbio Inc ANAB

$1.5B

Frequently Asked Questions

What is Rigel Pharmaceuticals Inc's annual revenue?

Rigel Pharmaceuticals Inc (RIGL) reported $179.3M in total revenue for fiscal year 2024. This represents a 53.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Rigel Pharmaceuticals Inc's revenue growing?

Rigel Pharmaceuticals Inc (RIGL) revenue grew by 53.4% year-over-year, from $116.9M to $179.3M in fiscal year 2024.

Is Rigel Pharmaceuticals Inc profitable?

Yes, Rigel Pharmaceuticals Inc (RIGL) reported a net income of $17.5M in fiscal year 2024, with a net profit margin of 9.8%.

What is Rigel Pharmaceuticals Inc's earnings per share (EPS)?

Rigel Pharmaceuticals Inc (RIGL) reported diluted earnings per share of $0.99 for fiscal year 2024. This represents a 168.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Rigel Pharmaceuticals Inc's EBITDA?

Rigel Pharmaceuticals Inc (RIGL) had EBITDA of $26.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Rigel Pharmaceuticals Inc have?

As of fiscal year 2024, Rigel Pharmaceuticals Inc (RIGL) had $56.7M in cash and equivalents against $60.0M in long-term debt.

What is Rigel Pharmaceuticals Inc's gross margin?

Rigel Pharmaceuticals Inc (RIGL) had a gross margin of 89.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Rigel Pharmaceuticals Inc's operating margin?

Rigel Pharmaceuticals Inc (RIGL) had an operating margin of 13.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Rigel Pharmaceuticals Inc's net profit margin?

Rigel Pharmaceuticals Inc (RIGL) had a net profit margin of 9.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Rigel Pharmaceuticals Inc's return on equity (ROE)?

Rigel Pharmaceuticals Inc (RIGL) has a return on equity of 531.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Rigel Pharmaceuticals Inc's operating cash flow?

Rigel Pharmaceuticals Inc (RIGL) generated $31.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Rigel Pharmaceuticals Inc's total assets?

Rigel Pharmaceuticals Inc (RIGL) had $164.0M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Rigel Pharmaceuticals Inc spend on research and development?

Rigel Pharmaceuticals Inc (RIGL) invested $23.4M in research and development during fiscal year 2024.

How many shares does Rigel Pharmaceuticals Inc have outstanding?

Rigel Pharmaceuticals Inc (RIGL) had 18M shares outstanding as of fiscal year 2024.

What is Rigel Pharmaceuticals Inc's current ratio?

Rigel Pharmaceuticals Inc (RIGL) had a current ratio of 2.13 as of fiscal year 2024, which is generally considered healthy.

What is Rigel Pharmaceuticals Inc's debt-to-equity ratio?

Rigel Pharmaceuticals Inc (RIGL) had a debt-to-equity ratio of 18.25 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rigel Pharmaceuticals Inc's return on assets (ROA)?

Rigel Pharmaceuticals Inc (RIGL) had a return on assets of 10.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Rigel Pharmaceuticals Inc's Altman Z-Score?

Rigel Pharmaceuticals Inc (RIGL) has an Altman Z-Score of -7.44, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Rigel Pharmaceuticals Inc's Piotroski F-Score?

Rigel Pharmaceuticals Inc (RIGL) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rigel Pharmaceuticals Inc's earnings high quality?

Rigel Pharmaceuticals Inc (RIGL) has an earnings quality ratio of 1.80x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Rigel Pharmaceuticals Inc cover its interest payments?

Rigel Pharmaceuticals Inc (RIGL) has an interest coverage ratio of 3.1x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Rigel Pharmaceuticals Inc?

Rigel Pharmaceuticals Inc (RIGL) scores 67 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.